Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer (SWOG 9916) (2004)

Peer-Reviewed Study · Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED · October 7, 2004

Petrylak DP et al., 2004-10-07: SWOG 9916 randomised 674 eligible men with metastatic hormone-independent prostate cancer to docetaxel plus estramustine or mitoxantrone plus prednisone. Median survival was 1.9 months longer with docetaxel (17.5 vs 15.6; HR 0.80), with more neutropenic fever, nausea/vomiting and cardiovascular events.

the median overall survival was longer in the group given docetaxel and estramustine than in the group given mitoxantrone and prednisone (17.5 months vs. 15.6 months, P=0.02 by the log-rank test), and the corresponding hazard ratio for death was 0.80

Abstract (RESULTS)

Petrylak DP et al., 2004-10-07: SWOG 9916 randomised 674 eligible men with metastatic hormone-independent prostate cancer to docetaxel plus estramustine or mitoxantrone plus prednisone. Median survival was 1.9 months longer with docetaxel (17.5 vs 15.6; HR 0.80), with more neutropenic fever, nausea/vomiting and cardiovascular events. Funder: National Cancer Institute cooperative group mechanism (SWOG); 'The SWOG Statistical Center received funding from Aventis Pharmaceuticals for the additional cost of collecting data on the quality of life. Aventis was allowed to review the protocol and make comments before enrollment began. Aventis had no access to the data'. Maker: Aventis (Taxotere) plus Pfizer (Emcyt estramustine). Comparator: mitoxantrone plus prednisone. This regimen (with estramustine) was not the regimen ultimately licensed. Study type: randomized trial.